Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST Sotorasib substudy for KRAS G12C-mutant advanced solid tumors excluding NSCLC and colorectal cancer
ACTRN12621001690842Phase 2Active, not recruiting
- Sponsor
- The University of Sydney
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotorasib in Nonhematologic neoplasms, sponsored by The University of Sydney. Started Jul 2022; status: active, not recruiting.
02
Drugs
sotorasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12621001690842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001690842.